The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases
Abstract Neurodegenerative disorders present complex pathologies characterized by various interconnected factors, including the aggregation of misfolded proteins, oxidative stress, neuroinflammation and compromised blood–brain barrier (BBB) integrity. Addressing such multifaceted pathways necessitates the development of multi-target therapeutic strategies. Emerging research indicates that probucol, a historic lipid-lowering medication, offers substantial potential in the realm of neurodegenerative disease prevention and treatment. Preclinical investigations have unveiled multifaceted cellular effects of probucol, showcasing its remarkable antioxidative and anti-inflammatory properties, its ability to fortify the BBB and its direct influence on neural preservation and adaptability. These diverse effects collectively translate into enhancements in both motor and cognitive functions. This review provides a comprehensive overview of recent findings highlighting the efficacy of probucol and probucol-related compounds in the context of various neurodegenerative conditions, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and cognitive impairment associated with diabetes..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Translational neurodegeneration - 13(2024), 1 vom: 22. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sharif, Arazu [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Amyloid-beta |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s40035-024-00398-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR05446773X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05446773X | ||
| 003 | DE-627 | ||
| 005 | 20240122064604.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40035-024-00398-w |2 doi | |
| 035 | |a (DE-627)SPR05446773X | ||
| 035 | |a (SPR)s40035-024-00398-w-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sharif, Arazu |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Abstract Neurodegenerative disorders present complex pathologies characterized by various interconnected factors, including the aggregation of misfolded proteins, oxidative stress, neuroinflammation and compromised blood–brain barrier (BBB) integrity. Addressing such multifaceted pathways necessitates the development of multi-target therapeutic strategies. Emerging research indicates that probucol, a historic lipid-lowering medication, offers substantial potential in the realm of neurodegenerative disease prevention and treatment. Preclinical investigations have unveiled multifaceted cellular effects of probucol, showcasing its remarkable antioxidative and anti-inflammatory properties, its ability to fortify the BBB and its direct influence on neural preservation and adaptability. These diverse effects collectively translate into enhancements in both motor and cognitive functions. This review provides a comprehensive overview of recent findings highlighting the efficacy of probucol and probucol-related compounds in the context of various neurodegenerative conditions, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and cognitive impairment associated with diabetes. | ||
| 650 | 4 | |a Neurodegenerative disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Probucol |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Probucol analogues |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Inflammation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Blood–brain barrier |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Oxidative stress |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Inflammation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Amyloid-beta |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Mamo, John |4 aut | |
| 700 | 1 | |a Lam, Virginie |4 aut | |
| 700 | 1 | |a Al-Salami, Hani |4 aut | |
| 700 | 1 | |a Mooranian, Armin |4 aut | |
| 700 | 1 | |a Watts, Gerald F. |4 aut | |
| 700 | 1 | |a Clarnette, Roger |4 aut | |
| 700 | 1 | |a Luna, Giuseppe |4 aut | |
| 700 | 1 | |a Takechi, Ryu |0 (orcid)0000-0001-6359-3382 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational neurodegeneration |d London : Biomed Central, 2012 |g 13(2024), 1 vom: 22. Jan. |w (DE-627)SPR032680694 |w (DE-600)2653701-1 |x 2047-9158 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:1 |g day:22 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s40035-024-00398-w |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 1 |b 22 |c 01 | ||